System Xc Inhibition Blocks Bone Marrow-multiple Myeloma Exosomal Crosstalk, Thereby Countering Bortezomib Resistance
Overview
Authors
Affiliations
Multiple myeloma (MM) cells derive proliferative signals from the bone marrow (BM) microenvironment via exosomal crosstalk. Therapeutic strategies targeting this crosstalk are still lacking. Bortezomib resistance in MM cells is linked to elevated expression of xCT (the subunit of system Xc). Extracellular glutamate released by system Xc can bind to glutamate metabotropic receptor (GRM) 3, thereby upregulating Rab27-dependent vesicular trafficking. Since Rab27 is also involved in exosome biogenesis, we aimed to investigate the role of system Xc in exosomal communication between BM stromal cells (BMSCs) and MM cells. We observed that expression of xCT and GRMs was increased after bortezomib treatment in both BMSCs and MM cells. Secretion of glutamate and exosomes was simultaneously enhanced which could be countered by inhibition of system Xc or GRMs. Moreover, glutamate supplementation increased exosome secretion by increasing expression of Alix, TSG101, Rab27a/b and VAMP7. Importantly, the system Xc inhibitor sulfasalazine reduced BMSC-induced resistance to bortezomib in MM cells in vitro and enhanced its anti-MM effects in vivo. These findings suggest that system Xc plays an important role within the BM and could be a potential target in MM.
Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.
Meena S, Kosgei B, Soko G, Tingjun C, Chambuso R, Mwaiselage J NPJ Vaccines. 2025; 10(1):18.
PMID: 39870669 PMC: 11772600. DOI: 10.1038/s41541-024-01035-3.
Xiao S, Chen L, Chen Z, Li Q Pharmaceutics. 2024; 16(11).
PMID: 39598562 PMC: 11597712. DOI: 10.3390/pharmaceutics16111439.
Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects.
Cheng H, Su G, Wu Y, Chen G, Yu Z J Pharm Anal. 2024; 14(7):100920.
PMID: 39104866 PMC: 11298875. DOI: 10.1016/j.jpha.2023.12.010.
Zhang J, Liu Y, Zuo L, Fan F, Yan H, Zhao F Blood Adv. 2024; 8(19):5022-5038.
PMID: 39042883 PMC: 11465055. DOI: 10.1182/bloodadvances.2023010335.
Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches.
Luo Y, Bai X, Zhang L, Hu Q, Zhang N, Cheng J Drug Des Devel Ther. 2024; 18:2485-2529.
PMID: 38919962 PMC: 11198730. DOI: 10.2147/DDDT.S472178.